Sildenafil
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
- Sildenafil
- Sildenafil: From an Unregistered Indication to Ambras Type Hypertrichosis Universalis Congenita
Using no additional skill — this is a direct document-generation task with an explicit template and complete input data, so I’ll produce the report directly.
Sildenafil: From an Unregistered Indication to Ambras Type Hypertrichosis Universalis Congenita
One-Sentence Summary
Sildenafil’s original indication cannot be characterized from this evidence pack — the drug is not currently marketed in this jurisdiction and no license records exist. The TxGNN model predicts a possible link to Ambras type hypertrichosis universalis congenita, an ultra-rare congenital hair-overgrowth syndrome, but this pairing is supported by zero clinical trials and zero publications, and the model’s own rationale flags it as a likely knowledge-graph artifact rather than a genuine mechanistic signal.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | No data available — drug is not marketed in this jurisdiction; 0 authorizations on file |
| Predicted New Indication | Ambras type hypertrichosis universalis congenita |
| TxGNN Prediction Score | 98.41% (rank 13,938 among all predictions) |
| Evidence Level | L5 |
| EU Market Status | ✗ Not Marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is currently unavailable for sildenafil in this evidence pack (flagged as a High-severity data gap, DG002). Separately within the same evidence pack, literature attached to a different candidate indication (PMID 30292404) describes sildenafil as a PDE5 inhibitor that increases intracellular cGMP and causes vasodilation — a mechanism that plausibly affects vascular/follicular tissue but has no established connection to Ambras type hypertrichosis, a congenital genetic overgrowth syndrome.
Critically, the model’s own repurposing rationale for this candidate states that the high TxGNN score “may reflect indirect connections in the knowledge graph with other hair/vascular-related nodes, without direct mechanistic evidence supporting sildenafil’s action in this indication.” In other words, this is very likely a graph-topology artifact (shared neighbors with unrelated hair/vascular nodes) rather than a biologically grounded hypothesis. Given the extreme rarity of this syndrome and complete absence of trials or literature, there is currently no basis to treat this as a credible repurposing signal.
Note for consideration: within this same evidence pack, a lower-ranked candidate — genetic alopecia (rank 9, score 75.03%) — has substantially stronger support: one completed early-phase RCT (NCT06527729, sildenafil lipid nanocarrier vs. placebo in alopecia areata, n=28), one additional relevant trial (NCT05369481, topical sildenafil vs. minoxidil), and a mechanistic publication (PMID 30292404) directly studying sildenafil’s effect on human hair follicles. That candidate is already scored L3 / Research Question stage and may warrant prioritized evaluation over the top-ranked but evidence-free Ambras hypertrichosis prediction.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
EU Market Information
Sildenafil has no marketing authorizations on file in this dataset (market_status: Not Marketed, total_licenses: 0). No license table can be generated.
Safety Considerations
Please refer to the SmPC for safety information.
(Note: key warnings and contraindications for this drug are recorded as a Blocking-severity data gap (DG001) — TFDA/label safety data has not yet been retrieved. This must be resolved before any safety evaluation (S1 stage) can proceed.)
Conclusion and Next Steps
Decision: Hold
Rationale: This candidate has no clinical trial or literature support, and the model’s own rationale identifies it as a likely spurious knowledge-graph connection rather than a genuine mechanistic hypothesis. In addition, two blocking data gaps — missing label/safety data (DG001, Blocking) and missing MOA documentation (DG002, High) — prevent this candidate from advancing past S0.
To proceed, the following is needed:
- TFDA/EMA label warnings and contraindications (DG001 — currently blocking)
- Confirmed mechanism-of-action documentation for sildenafil (DG002)
- Any direct preclinical or mechanistic evidence specifically linking sildenafil to Ambras type hypertrichosis (currently none exists)
- Consider redirecting evaluation effort toward the better-evidenced genetic alopecia candidate (rank 9, L3, Research Question) identified in the same evidence pack, which already has a completed RCT and supporting mechanistic literature
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.